ALK-Abelló A/S clinical trials

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company

Part of Lundbeckfond Invest A/S, which holds 40.3% of capital; 67.2% of voting rights as of 2025-12-31. Source

The registry lists 72 studies whose lead sponsor is ALK-Abelló A/S or one of 3 companies grouped under it. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 5, 2026.

Keep track of what changes. Save the ALK-Abelló A/S studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

Status

Completed: 67
Terminated: 2
Status unknown: 1
Recruiting: 1
Enrolling by invitation: 1

Phase

Phase 3: 39
Phase 2: 24
Phase 4: 6
Phase 1: 6

Where

Germany: 18
Spain: 13
France: 9
Denmark: 8
Poland: 7
United States: 6

Focus areas

Conditions ALK-Abelló A/S leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Rhinitis28 Rhinitis, Allergic28 Conjunctivitis16 Hypersensitivity13

Studies

Recruiting first, then most recently updated. Showing 50 of 72. Browse all 72 →

ALK-Abelló A/S clinical trials

Status

Phase

Where

Registry sponsor names on this page

Focus areas

Studies